anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: In the United States, an estimated $2.8 billion annually is spent on vascular access and its complications. Endovascular arteriovenous fistula (endoAVF) creation is a novel, minimally invasive alternative to traditional surgical AV fistula (sAVF) creation in ≤60% of patients. Although cost effective in single-payer systems, the clinical and financial impact of endoAVF in the United States remains uncertain.
METHODS: We constructed a decision tree followed by a probabilistic cohort state-transition model to study the cost effectiveness of endoAVF vs sAVF creation. We conducted a systematic review to obtain input parameters including technical success, maturation, patency, and utility values. We derived costs from the Medicare 2022 fee schedule and from the literature. We used a 5-year time horizon, an annual discount rate of 3% for costs and utilities (measured in quality-adjusted life-years [QALYs]), and the common willingness-to-pay threshold of $50,000. One-way and Monte Carlo probabilistic sensitivity analyses were performed varying technical success, patency, reintervention, cost, and utility parameters.
RESULTS: In the base-case scenario, endoAVF ($30,129 average per-person costs, 2.19 QALYs gained, 65% patent at 5 years) was not cost effective compared with sAVF ($12.987 average per-person costs, 2.11 QALYs gained, 66% patent at 5 years), generating an incremental cost-effectiveness ratio of $227,504 per QALY gained. In one-way sensitivity analyses, endoAVF becomes cost effective when the initial cost of sAVF creation exceeds endoAVF by ≥$600 (eg, if endoAVF creation costs ≤$3000 relative to the base-case sAVF cost of $3600), the additional QALYs gained from endoAVF exceeds 0.12 QALYs/year (eg, 0.81 QALYs gained/year from endoAVF compared with base-case sAVF 0.69 QALYs/year), the endoAVF maturation rate is >90% (base case 78%), or the sAVF maturation rate is <65% (base case 78%). Probabilistic sensitivity analysis demonstrated that sAVF remained the optimal strategy in 71% of iterations.
CONCLUSIONS: EndoAVF is not cost effective compared with sAVF when modeling 5-year outcomes. The main driver of sAVF remaining cost effective is the four times higher up-front cost for endoAVF creation, as well as a relatively low additional increase in quality of life for endoAVF. It will be important to establish how the endoAVF learning curve contributes to upfront costs and, given the annual cost attributed to vascular access nationally, a randomized controlled trial is warranted.
Treatment of damaged, diseased, abnormal, infarcted, cancerous, or undesirable tissue (e.g., tumors, benign tumors, malignant tumors, cysts, or areas of diseased tissue, etc.) is provided by delivering specific Pulsed Electric Field (PEF) energy to the targeted tissue area at specific doses in order to achieve superior results. PEF energy and delivery are optimized to provide advanced treatment of the target tissue region, including destruction of unwanted tissue and generation of improved inflammatory and immune responses. These various types of treatments are controlled by a variety of factors including electrode geometry, the dose of PEF energy delivered, the time of energy delivery, and the waveform of the PEF energy itself. PEF energy is delivered in the form of a dose, which is considered to be one application of dedicated energy. Each dose creates lesions in the target tissue region.
Placebo given on Day 1 and Day 15. ART will be given throughout the study.
BACKGROUND: Dysbiosis during childhood impacts the configuration and maturation of the microbiota. The immaturity of the infant microbiota is linked with the development of inflammatory, allergic, and dysmetabolic diseases.
AIMS: To identify taxonomic changes associated with age and GDM and classify the maturity of the intestinal microbiota of children of mothers with GDM and children without GDM (n-GDM).
METHODS: Next-generation sequencing was used to analyze the V3-V4 region of 16S rRNA gene. QIIME2 and Picrust2 were used to determine the difference in the relative abundance of bacterial genera between the study groups and to predict the functional profile of the intestinal microbiota.
RESULTS: According to age, the older GDM groups showed a lower alpha diversity and different abundance of Enterobacteriaceae, Veillonella, Clostridiales, and Bacteroides. Regarding the functional profile, PWY-7377 and K05895 associated with Vitamin B12 metabolism were reduced in GDM groups. Compared to n-GDM group, GDM offspring had microbiota immaturity as age-discriminatory taxa in random forest failed to classify GDM offspring according to developmental age (OOB error 81%). Conclusion. Offspring from mothers with GDM have a distinctive taxonomic profile related to taxa associated with gut microbiota immaturity.
In induction period, group A received dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline 10 minute through a syringe pump. Three minutes before application of skull pins, group A received infusion of 2 ml of 0.9% normal saline.
PURPOSE: To obtain an emulsion composition excellent in emulsion stability with the lapse of time without using a surfactant by incorporating an alkyl modified carboxyl vinyl polymer and a higher alcohol having a specific carbon number and liquid at ordinary temp. CONSTITUTION: This emulsion composition is obtained by incorporating an alkyl modified carboxyl vinyl polymer and a 12-28C higher alcohol liquid at room temp. (25 deg.C). The alkyl modified carboxyl vinyl polymer used in this case is an acrylic methacrylic alkyl copolymer and its blending quantity is preferably 0.05-5wt.% in the emulsion composition. As the 12-28C higher alcohol liquid at room temp. (25 deg.C), tridecyl alcohol, isostearyl alcohol, hexyl decanol, octyl dodecanol, decyl tetradecanol, heptyl undecanol, oleyl alcohol, jojoba alcohol and the like are exemplified and its blended quantity is preferably 0.5-5wt.%.
The high prevalence of stress-related disorders and depression underscores the urgent need to unravel their impact on individual well-being. This study aim to investigate common psychiatric and stress-related diagnoses, along with postviral fatigue, in individuals with prior stress-induced exhaustion disorder (SED) and prior depression compared to those without prior SED or depression, and to study whether the psychiatric comorbidity patterns differ. The study includes individuals in Region Stockholm who, in 2011, did not have a diagnosis of SED or depression. ICD-10 diagnosis of SED, depression, or both, recorded in 2012-2013, were compared to individuals without prior SED or depression in a cohort (n = 1,362,886), aged 18 to 65. Odds ratios (OR) with 99 % confidence intervals, adjusted for age and neighborhood socioeconomic status, were calculated for psychiatric disorders and post-viral fatigue in 2014-2022. Patients with prior SED showed associations primarily with stress related diagnoses, including acute stress reaction, reaction to severe stress, as well as post-COVID-19 and post-viral fatigue syndrome. These ORs were all larger for SED than depression. Depression was primarily associated with post-traumatic stress disorder (PTSD), alcohol related and substance use disorders, schizophrenia, schizotypal disorders, delusional disorders, manic episode, bipolar affective disorder, persistent mood disorder, neurotic disorder, borderline personality disorder, autistic disorder, Asperger's syndrome, attention -deficit hyperactivity disorder, attention-deficit disorders ADHD/ADD), and suicide attempt. These ORs were all higher for depression, although autistic disorders, ADHD/ADD and PTSD were also highly associated with prior SED (OR > 3.5). The divergent psychiatric comorbidity patterns suggest different underlying mechanisms and clinical prognosis.
Because tumors may have multiple mechanisms to induce angiogenesis, blockade with sorafenib may demonstrate efficacy. Doses of sorafenib (400 mg b.i.d.) as a single agent is with minimal toxicity, presents an opportunity to explore a more intensive drug administration. This study will allow individual patient titration (e,g,, intrapatient dose escalation) as per protocol.

This provides the basis for the dose escalation development of sorafenib. The study is designed to evaluate the ability for patients to dose escalate. Secondary endpoints include; response, time to progression, and overall survival in patients with MRCC. Tissue correlation to evaluate the impact of expression of receptor on clinical outcome will be retrospectively performed. Laboratory correlation of plasma VEGF levels will be correlated and evaluated to clinical outcome.
Part 2: Open-label ZX008 will be administered using a flexible dosing regimen, up to ZX008 0.8 mg/kg/day; maximum dose: 30 mg/day (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, \[maximum of 20 mg/day\]). ZX008 will be administered twice a day (BID) in equally divided doses with or without food.
The invention discloses a separation and purification process for islet separation and purification in islet transplantation and application thereof. In the invention, the density gradient centrifugation method can effectively separate islet cells from other cells. Because of the different densities of different cells, the gradient centrifugation solution can create a density gradient, so that islet cells are concentrated at specific positions in the gradient, and the purity of the islet cells is improved. The gradient centrifugation solution has a good protection effect on islet cells, and can reduce cell damage caused by mechanical force in the centrifugation process. This protection helps to maintain the activity and function of the islet cells, providing high quality cells for subsequent islet transplantation. The islet cells with higher purity obtained by the density gradient centrifugation method can reduce the occurrence of immune rejection reaction after transplantation and improve the success rate of islet transplantation.
Volunteers will be asked to consume a standard meal (lunch) containing one serving of mushrooms daily for six weeks (7 days per week). With the meal, they will also need to take one capsule. The capsule will be either a placebo or will contain vitamin D. The purpose of the vitamin D in the capsule is to determine if the vitamin D from the mushrooms is absorbed as well as vitamin D from a capsule. The total dose of vitamin D that volunteers will receive each day from mushrooms and capsule together will always be the same and will be one of three doses: (1) little or no vitamin D (placebo); (2) 400 IU, which is near the current recommended intake and (3) 1,000 IU, which is up to five-fold higher than the current recommended intake, depending on your age. Both levels of vitamin D are safe. In addition to consuming the meals and taking the capsules, up to 20 mL (4 teaspoons) of blood will be drawn at three times during the study just before the mushroom-containing lunch is provided: (1) at the beginning of the study before the first meal; (3) after three weeks; (3) at the end of the study. The purpose of the blood draw is to measure vitamin D in your blood and to measure the level of activation of your immune system by measuring markers of immune activation.
A method of manufacturing an E. coli inhibiting composition that includes live Lactobacillus animalis and/or live Lactobacillus acidophilus bacterial cells. The composition can be ingested to prevent E. coli in animals, or applied as a surface treatment on things, including food items. The manufacturing method includes inoculating a bacterial fermentation medium with live Lactobacillus cells and harvesting live Lactobacillus cells at least partially between mid-log and late-log phase of growth. The harvesting of live Lactobacillus cells can occur at least partially during early-log, mid-log and late-log phase of growth. Prior to harvesting, the cell count of live Lactobacillus cells can be required to be at least 1×106 cells/ml, after which the live Lactobacillus live cell count can be concentrated to at least 5×109 cells/ml. For stability and shelf-life, optionally, the Lactobacillus can be harvested when the live cells are substantially round or spherically shaped, and before the cells grow to an elongate shape.
To explore the risk factors for residual symptoms following percutaneous endoscopic lumbar discectomy (PELD). A retrospective case-controlled study. From January 2015 to December 2020, consecutive patients who underwent PELD for lumbar disc herniation (LDH) in our department were retrospectively studied. All the patients were followed-up at least two years. Residual symptoms were analyzed for association with baseline data, clinical feature, physical examination, and radiographic characteristics, which were used to detected the risk factors. A total of 339 patients were included in this study, with a mean follow-up of 28.7 ± 3.6 months. Of the enrolled patients, 90 (26.5%) patients experienced residual low back pain (LBP), and 76 (22.4%) patients experienced leg numbness (LN). Multivariate logistic regression analysis revealed that intervertebral disc calcification on CT scans (odd ratio, 0.480; 95% confidence interval: 0.247 ~ 0.932; P < 0.05) was independent risk factor for postoperative residual LBP with odd ratio and longer symptom duration was risk factor for postoperative residual LN (odd ratio, 2.231; 95% confidence interval:1.066 ~ 4.671; P < 0.05). Residual symptoms following transforaminal endoscopic surgery are quite prevalent. Intervertebral disc calcification is a protective factor for residual low back pain, and a longer symptom duration is a risk factor for residual leg numbness.
Mindfulness Based Cognitive therapy (MBCT) will consist of group meditative practices, lasting 2 hours per week (or whatever the patient can tolerate). The interventions will be conducted at the "centre local de services communautaires" (CLSC) Benny Farm, once a week. Patients will be invited to try various techniques during sessions. The patients will be encouraged to practice the Mindfulness techniques, that includes formal mindfulness meditation and informal mindfulness practices (e.g. being in the present moment while not meditating), at home, between sessions, and will be provided with meditation compact discs to help them do so. MBCT interventions also include a cognitive therapy perspective. Specifically, the interventionists will offer education regarding depression and anxiety and will work on automatic mental processes that are believed to be at the root of the recurrence of depressive and anxious symptoms.
Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
Gestational diabetes rates are globally increasing and it is now well known that women who had gestational diabetes have a recurrent risk ranging from 35.5% to 70% in a future pregnancy. Some of these women may have preexisting type 2 diabetes or glucose intolerance There is also now convincing evidence that the women with GDM are at increased risk of T2DM and cardiovascular disorders. GDM can also affect the health of the offspring and associated with an increased risk of future obesity, diabetes and cardiovascular disorders, possibly modulated through altered epigenetics of the fetus. The recent NICE guidance has recommended that women with a history of GDM should be offered early pregnancy glucose monitoring or testing with oral glucose tolerance test at 24-28 weeks. Gestational diabetes is associated with derangement in amino acid and lipid pathways and these changes can be demonstrated several weeks prior to the diagnosis of GDM. Similarly, both candidate gene and genome wide studies have reported that GDM exposure is associated with significant changes in the infant's or child's DNA methylation, with a recent meta-analysis of seven pregnancy cohorts identified differentially methylated regions (DMRs) associated with GDM within OR2L13 and CYP2E1. Others have also been able to demonstrate that GDM-associated methylation is associated with offspring obesity and T2DM.

There is emerging evidence that in pregnancy gestational diabetes can occur as early as the first trimester. However in clinical practice, screening and diagnosis does not occur until 28 weeks in the pregnancy, suggesting that in some cases the fetus may be exposed to undetected hyperglycaemia much earlier. There is varying practice in how a pregnant women with a history of GDM is managed in a future pregnancy. Some are offered early capillary blood glucose testing four times a day as early as 10 weeks (early monitoring), while others are offered diagnostic testing with an oral glucose tolerance test at 28 weeks (late monitoring). This study was designed to compare the pregnancy outcomes between the early and the late monitoring approaches to determine which is more effective in modulating the maternal metabolome, placental insulin signalling pathways and offspring DNA methylation. Equally important the multi-centre observational arm will allow comparison of maternal and neonatal outcomes between both groups.
PURPOSE:To obtain a detergent composition free from sticky feeling after drying the cleaned object and having excellent usability and conditioning effect by dispersing a mixture of water-insoluble polymer powder and a water-insoluble nonvolatile silicone in an aqueous solution of a surfactant. CONSTITUTION:A mixture of 0.01-10wt.% of water-insoluble polymer powder (e.g. water-insoluble silicone resin powder 'Tospar(R)' produced by Toshiba Silicone Co.) and 0.01-10wt.% of a water-insoluble nonvolatile silicone (e.g. dimethylpolysiloxane) is dispersed in an aqueous solution of a surfactant (e.g. sodium polyoxyethylene lauryl ether sulfate) in an amount of 5-30 wt.%. The weight ratio of the water-insoluble polymer powder to the water-insoluble nonvolatile silicone is preferably 1:(100-20) and the total amount of the components in the detergent composition is 0.1-10wt.%. The composition can be used as hair shampoo, body shampoo, etc. It is stable over a long period in spite of the presence of silicone.
PURPOSE:To efficiently purify blood contg. a carcinostatic by separating this blood to plasma contg. the carcinostatic and blood cell components by a plasma separator and irradiating the plasma with light, thereby inducing a photochemical reaction in the carcinostatic in the blood and converting the carcinostatic to a low-toxicity material. CONSTITUTION:The blood contg. the carcinostatic m closed to the human body is delivered by a pump 14 into a pipe 12 and is separated to the plasma contg. the carcinostatic and the blood cell components by the hollow yarn plasma separator 16. The plasma is delivered by a pump 20 into a quartz cell 18. The quartz cell 18 to which the plasma is delivered is irradiated with the laser beam which is outputted from an XeCl excimer laser 22 and is reflected by a quartz prism 24. The carcinostatic is converted to the low-toxicity material by such irradiation with the laser beam. The plasma contg. the low-toxicity material converted in such a manner is combined with the blood cell components at a confluent point 2a of a pipe 12, by which the blood is recomposed. This blood is returned to the living body.
BACKGROUND: Botulinum toxin type A (BTX-A), produced by the gram-positive anaerobic bacterium Clostridium botulinum, acts by cleaving synaptosome-associated protein-25 (SNAP-25), an essential component of the presynaptic neuronal membrane that is necessary for fusion with the membrane proteins of neurotransmitter-containing vesicles. Recent studies have highlighted the efficacy of BTX-A in treating chronic pain conditions, including lower back pain, chronic neck pain, neuropathic pain, and trigeminal neuralgia, particularly when patients are unresponsive to traditional painkillers. This review focuses on the analgesic effects of BTX-A in various chronic pain conditions, with a particular emphasis on the orofacial region.
HIGHLIGHT: This review focuses on the mechanisms by which BTX-A induces analgesia in patients with inflammatory and temporomandibular joint pain. This review also highlights the fact that BTX-A can effectively manage neuropathic pain and trigeminal neuralgia, which are difficult-to-treat chronic pain conditions. Herein, we present a comprehensive assessment of the central analgesic effects of BTX-A and a discussion of its various applications in clinical dental practice.
CONCLUSION: BTX-A is an approved treatment option for various chronic pain conditions. Although there is evidence of axonal transport of BTX-A from peripheral to central endings in motor neurons, the precise mechanism underlying its pain-modulating effects remains unclear. This review discusses the evidence supporting the effectiveness of BTX-A in controlling chronic pain conditions in the orofacial region. BTX-A is a promising therapeutic agent for treating pain conditions that do not respond to conventional analgesics.
Sepsis-induced myocardial dysfunction commonly occurs in individuals with sepsis and is a severe complication with high morbidity and mortality rates. This study aimed to investigate the effects and potential mechanisms of the natural steroidal sapogenin ruscogenin (RUS) against lipopolysaccharide (LPS)-induced myocardial injury in septic mice. We found that RUS effectively alleviated myocardial pathological damage, normalized cardiac function, and increased survival in septic mice. RNA sequencing demonstrated that RUS administration significantly inhibited the activation of the NOD-like receptor signaling pathway in the myocardial tissues of septic mice. Subsequent experiments further confirmed that RUS suppressed myocardial inflammation and pyroptosis during sepsis. In addition, cultured HL-1 cardiomyocytes were challenged with LPS, and we observed that RUS could protect these cells against LPS-induced cytotoxicity by suppressing inflammation and pyroptosis. Notably, both the in vivo and in vitro findings indicated that RUS inhibited NOD-like receptor protein-3 (NLRP3) upregulation in cardiomyocytes stimulated with LPS. As expected, knockdown of NLRP3 blocked the LPS-induced activation of inflammation and pyroptosis in HL-1 cells. Furthermore, the cardioprotective effects of RUS on HL-1 cells under LPS stimulation were abolished by the novel NLRP3 agonist BMS-986299. Taken together, our results suggest that RUS can alleviate myocardial injury during sepsis, at least in part by suppressing NLRP3-mediated inflammation and pyroptosis, highlighting the potential of this molecule as a promising candidate for sepsis-induced myocardial dysfunction therapy.